Status:
COMPLETED
Thyroid Hormone Supplementation in Patients With Septic Shock
Lead Sponsor:
Cantonal Hospital Zenica
Conditions:
Euthyroid Sick Syndromes
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The primary aim of the study would be to determine whether there is a difference in survival in the Intensive Care Unit between the group of patients with septic shock diagnosed with euthyroid sick sy...
Eligibility Criteria
Inclusion
- all patients who meet the criteria for septic shock according to the definition of Surviving sepsis campaigning (The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016): persistent hypotension requiring the use of vasoactive drugs to maintain mean arterial pressure ≥65 mm Hg ; blood lactates\> 2 mmol / L despite adequate resuscitation volume,
- patients with laboratory-proven euthyroid sick syndrome, according to diagnostic criteria which include: normal levels of TSH hormone, low levels of T3 hormone that may accompany low levels of T4 hormone (depending on the stage of critical disease) and absence of previous primary thyroid and pituitary disease.
Exclusion
- age below 18,
- patients with a history of thyroid disease or an enlarged thyroid gland,
- psychiatric patients,
- patients on hormone therapy (excluding insulin),
- those taking amiodarone, corticosteroids or dopamine
- pregnant or postpartum mothers 6 months ago,
- patients who refuse to participate in the study
Key Trial Info
Start Date :
May 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT05270798
Start Date
May 1 2022
End Date
August 1 2023
Last Update
September 28 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cantonal Hospital
Zenica, Bosnia and Herzegovina, 72000